{"log_id": 566540114708914885, "direction": 0, "words_result_num": 61, "words_result": [{"probability": {"variance": 2.2e-05, "average": 0.997914, "min": 0.975291}, "location": {"width": 877, "top": 151, "height": 65, "left": 191}, "words": "体外研究显示加巴喷丁在大鼠脑内的结合位点分布于新皮层和海马,其高亲和力的结合蛋白被证实为电压激活"}, {"probability": {"variance": 0.00023, "average": 0.99082, "min": 0.94671}, "location": {"width": 331, "top": 208, "height": 39, "left": 145}, "words": "钙通道的辅助亚单位,相关功能尚未阐明"}, {"probability": {"variance": 0.001716, "average": 0.987311, "min": 0.736849}, "location": {"width": 878, "top": 240, "height": 66, "left": 192}, "words": "遗传毒性加巴喷丁Ames试验、 CHL HGPRT突变试验、CHL染色体畸变试验、中国仓鼠骨髓染色体畸变试验"}, {"probability": {"variance": 8e-06, "average": 0.997578, "min": 0.992788}, "location": {"width": 78, "top": 249, "height": 23, "left": 193}, "words": "毒理研究"}, {"probability": {"variance": 0.001243, "average": 0.987406, "min": 0.791879}, "location": {"width": 669, "top": 282, "height": 56, "left": 150}, "words": "和微核试验、小鼠微核试验、大鼠肝细胞程序外DNA合成试验(UDS)结果均为阴性"}, {"probability": {"variance": 0.006488, "average": 0.957906, "min": 0.658865}, "location": {"width": 877, "top": 301, "height": 65, "left": 194}, "words": "生殖毒性一般生殖毒性:大鼠经口给予加巴喷丁(5001000和200mg/kg/天)后,所有胎仔均受影响。致"}, {"probability": {"variance": 0.001354, "average": 0.984769, "min": 0.756309}, "location": {"width": 922, "top": 331, "height": 67, "left": 151}, "words": "畸敏感期毒性:妊娠小鼠经口给予加巴喷丁1000或3000mg/kg/天,出现胚胎毒性,头骨、椎骨、前肢和后肢骨骼"}, {"probability": {"variance": 0.0063, "average": 0.981415, "min": 0.479557}, "location": {"width": 686, "top": 371, "height": 57, "left": 152}, "words": "骨化延迟,无毒剂量为500mg/kg/天。围产期毒性:家兔给予加巴喷丁60,300和15"}, {"probability": {"variance": 0.000358, "average": 0.987325, "min": 0.938252}, "location": {"width": 196, "top": 362, "height": 35, "left": 880}, "words": "kg/天,植入后胎仔丢失"}, {"probability": {"variance": 0, "average": 0.998907, "min": 0.998306}, "location": {"width": 57, "top": 432, "height": 21, "left": 154}, "words": "率增加"}, {"probability": {"variance": 0.005341, "average": 0.985526, "min": 0.441348}, "location": {"width": 878, "top": 419, "height": 64, "left": 200}, "words": "另外,在大鼠一般生殖毒性试验(经口给药2000mg/kg)、致畸敏感期毒性试验(1500mg/kg)、围产期毒性试"}, {"probability": {"variance": 0.008124, "average": 0.977484, "min": 0.38731}, "location": {"width": 923, "top": 450, "height": 64, "left": 155}, "words": "验(500,1000和2000mg/kg)中,大鼠输尿管积水和/或肾盂积水的发生率升高按体表面积比推算,小鼠、大鼠"}, {"probability": {"variance": 0.001414, "average": 0.990964, "min": 0.766624}, "location": {"width": 659, "top": 489, "height": 55, "left": 158}, "words": "和家兔给予加巴喷丁的剂量分别为人用剂量的4、5、8倍时,未见畸胎发生率增加"}, {"probability": {"variance": 0.005455, "average": 0.968028, "min": 0.616443}, "location": {"width": 881, "top": 506, "height": 65, "left": 201}, "words": "致癌作用:小鼠和大鼠分别经口给予加巴喷丁200、60、2000mg/kg/天和250、1000、2000mg/kg/天,连续"}, {"probability": {"variance": 0.001722, "average": 0.988174, "min": 0.734356}, "location": {"width": 929, "top": 536, "height": 65, "left": 154}, "words": "2年。结果发现高剂量组雄性动物胰腺腺泡细胞瘤和胰腺腺泡细胞癌发生率明显升高,但未影响动物存活,也未出现"}, {"probability": {"variance": 0.000783, "average": 0.9925, "min": 0.817437}, "location": {"width": 925, "top": 565, "height": 65, "left": 159}, "words": "转移和浸润。研究提示,加巴喷丁在体外可促进大鼠胰腺腺泡细胞的DNA合成,因此,其可能为一种增强有丝分裂"}, {"probability": {"variance": 0.001297, "average": 0.986636, "min": 0.80484}, "location": {"width": 642, "top": 605, "height": 53, "left": 160}, "words": "的促癌剂。但加巴喷丁对其他细胞和种属(包括人)促细胞增殖的作用尚不明确"}, {"probability": {"variance": 2.4e-05, "average": 0.996977, "min": 0.973409}, "location": {"width": 876, "top": 620, "height": 65, "left": 208}, "words": "临床研究显示,2085名长期服药的患者(大于12岁),在停止服用加巴喷丁后2年内有10名患者出现了新的"}, {"probability": {"variance": 0.003125, "average": 0.980777, "min": 0.630585}, "location": {"width": 922, "top": 651, "height": 62, "left": 164}, "words": "肿瘤(2例乳腺癌、3例脑癌、2例肺癌、1例肾上腺瘤、1例非何杰金氏淋巴瘤和1例子宫内膜癌),11名患者出现"}, {"probability": {"variance": 0.006498, "average": 0.984161, "min": 0.418421}, "location": {"width": 924, "top": 679, "height": 62, "left": 163}, "words": "肿瘤恶化(其中9例脑癌、1例乳腺癌、1例前列腺癌)由于没有未经过加巴喷丁治疗的相似人群在肿瘤发生和复"}, {"probability": {"variance": 7e-06, "average": 0.998492, "min": 0.986768}, "location": {"width": 535, "top": 722, "height": 49, "left": 165}, "words": "发率上的背景资料,因此不确定以上肿瘤的发生或恶化与治疗有关"}, {"probability": {"variance": 6.2e-05, "average": 0.996353, "min": 0.949475}, "location": {"width": 877, "top": 762, "height": 65, "left": 213}, "words": "据文献报道,服用加巴喷丁后所有的药理学作用都来自于其母体化合物的活性,加巴喷丁在人体的代谢是不明"}, {"probability": {"variance": 4e-06, "average": 0.998581, "min": 0.994749}, "location": {"width": 122, "top": 770, "height": 30, "left": 172}, "words": "【药代动力学】"}, {"probability": {"variance": 1.2e-05, "average": 0.987884, "min": 0.984401}, "location": {"width": 36, "top": 832, "height": 21, "left": 172}, "words": "显的"}, {"probability": {"variance": 0.001876, "average": 0.988241, "min": 0.732016}, "location": {"width": 804, "top": 823, "height": 59, "left": 215}, "words": "口服生物利用度:加巴喷丁的生物利用度与剂量不成比例,当剂量增加时,生物利用度下降。在每日"}, {"probability": {"variance": 0, "average": 0.836437, "min": 0.836437}, "location": {"width": 20, "top": 823, "height": 20, "left": 1070}, "words": "给"}, {"probability": {"variance": 0.000103, "average": 0.994511, "min": 0.957843}, "location": {"width": 496, "top": 857, "height": 45, "left": 407}, "words": "300和4800mg加巴喷丁时,其生物利用度分别约为60%、47"}, {"probability": {"variance": 0.004181, "average": 0.963025, "min": 0.830641}, "location": {"width": 117, "top": 851, "height": 25, "left": 978}, "words": "83%和27%。食"}, {"probability": {"variance": 0.012361, "average": 0.950299, "min": 0.574425}, "location": {"width": 195, "top": 881, "height": 32, "left": 173}, "words": "予剂量为900、1200、24"}, {"probability": {"variance": 0, "average": 0.929455, "min": 0.929455}, "location": {"width": 61, "top": 878, "height": 23, "left": 970}, "words": "公"}, {"probability": {"variance": 0.000273, "average": 0.99401, "min": 0.902973}, "location": {"width": 602, "top": 891, "height": 51, "left": 172}, "words": "物对加巴喷丁的吸收速度和程度只有轻微的影响AUC和C有14%的增加)"}, {"probability": {"variance": 0.006193, "average": 0.980609, "min": 0.441184}, "location": {"width": 875, "top": 903, "height": 67, "left": 220}, "words": "分布:加巴喷丁在循环中大部分不与血浆蛋白结合(蛋白结合率<3%)静脉注射加巴喷丁150mg后的表观分"}, {"probability": {"variance": 0.00648, "average": 0.973295, "min": 0.46881}, "location": {"width": 884, "top": 935, "height": 64, "left": 176}, "words": "布容积为58±6L(平均值土标准差)癫痫患者脑脊液中加巴喷丁稳态谷浓度(C)大约为相应血浆浓度的20"}, {"probability": {"variance": 0.000393, "average": 0.995303, "min": 0.862419}, "location": {"width": 877, "top": 963, "height": 62, "left": 221}, "words": "消除:加巴喷丁主要以原形通过肾脏排泄从全身循环系统中消除,在人体内的代谢不明显加巴喷丁的消除半"}, {"probability": {"variance": 0.002745, "average": 0.982054, "min": 0.73231}, "location": {"width": 973, "top": 975, "height": 88, "left": 178}, "words": "哀期是5~7小时,并且不随剂量或多次给药而改变。加巴喷丁的消除速率常数、血浆清除和肾清除与肌酐清除率直"}, {"probability": {"variance": 0.003966, "average": 0.982026, "min": 0.610464}, "location": {"width": 927, "top": 1018, "height": 68, "left": 180}, "words": "接成正比(见特殊人群中肾脏功能不全的患者)。在老年患者和肾脏功能损伤的患者,加巴喷丁血浆清除率下降。加"}, {"probability": {"variance": 7e-05, "average": 0.997263, "min": 0.963965}, "location": {"width": 315, "top": 1075, "height": 37, "left": 180}, "words": "巴喷丁可以通过血液透析从血浆中清除"}, {"probability": {"variance": 0.001362, "average": 0.985559, "min": 0.824446}, "location": {"width": 647, "top": 1085, "height": 56, "left": 226}, "words": "特殊人群:肾功能不全的成年患者:肾功能不全(平均肌酐清除率为13~114mL"}, {"probability": {"variance": 0.002142, "average": 0.976764, "min": 0.839529}, "location": {"width": 177, "top": 1079, "height": 28, "left": 926}, "words": "的受试者(N=60)单"}, {"probability": {"variance": 5.9e-05, "average": 0.996096, "min": 0.97219}, "location": {"width": 203, "top": 1126, "height": 35, "left": 395}, "words": "加巴喷丁的平均半衰期为"}, {"probability": {"variance": 0.005921, "average": 0.972686, "min": 0.571674}, "location": {"width": 468, "top": 1106, "height": 44, "left": 636}, "words": "小时(肌酐清除率>60mL/min的患者)~52小时(肌酐清"}, {"probability": {"variance": 0.000218, "average": 0.992321, "min": 0.949077}, "location": {"width": 174, "top": 1138, "height": 33, "left": 181}, "words": "剂量口服加巴喷丁40"}, {"probability": {"variance": 0.001849, "average": 0.982284, "min": 0.802673}, "location": {"width": 470, "top": 1153, "height": 47, "left": 183}, "words": "除率<30mL/min的患者),加巴喷丁的肾脏清除率为90mL"}, {"probability": {"variance": 0.006381, "average": 0.961888, "min": 0.710474}, "location": {"width": 400, "top": 1136, "height": 40, "left": 704}, "words": "肌酐清除率>60mL/min的患者)~10mL/min(肌"}, {"probability": {"variance": 0.015222, "average": 0.94896, "min": 0.600785}, "location": {"width": 138, "top": 1202, "height": 24, "left": 185}, "words": "酐清除率<30mL"}, {"probability": {"variance": 0.011016, "average": 0.962834, "min": 0.424688}, "location": {"width": 472, "top": 1175, "height": 45, "left": 363}, "words": "的患者)平均血浆清除率从大约190mL/min下降到20mL"}, {"probability": {"variance": 0.009579, "average": 0.97862, "min": 0.499278}, "location": {"width": 460, "top": 1210, "height": 44, "left": 232}, "words": "肾功能损伤的患者或进行血液透析的患者需进行剂量调整"}, {"probability": {"variance": 1.1e-05, "average": 0.998456, "min": 0.987036}, "location": {"width": 298, "top": 1246, "height": 36, "left": 231}, "words": "肾功能不全的儿科患者尚未进行研究"}, {"probability": {"variance": 0.003741, "average": 0.976657, "min": 0.751574}, "location": {"width": 838, "top": 1249, "height": 64, "left": 234}, "words": "血液透析:在无尿症的患者的研究中(N1),加巴喷丁在未透析时的表观消除半衰期大约为132个小时"}, {"probability": {"variance": 0.001563, "average": 0.987886, "min": 0.726211}, "location": {"width": 916, "top": 1278, "height": 64, "left": 188}, "words": "周透析三次(每次持续4小时),加巴喷丁的表观消除半衰期从132小时减少到51小时,减少了大约60%。由此可见"}, {"probability": {"variance": 1.5e-05, "average": 0.997971, "min": 0.981466}, "location": {"width": 427, "top": 1327, "height": 45, "left": 189}, "words": "血液透析对无尿症患者体内加巴喷丁的消除影响很大"}, {"probability": {"variance": 0.000244, "average": 0.992556, "min": 0.941879}, "location": {"width": 260, "top": 1361, "height": 37, "left": 237}, "words": "血液透析的患者需进行剂量调整"}, {"probability": {"variance": 0.000763, "average": 0.990846, "min": 0.853004}, "location": {"width": 555, "top": 1376, "height": 51, "left": 236}, "words": "肝疾患者:由于加巴喷丁不代谢,所以未对肝脏损伤的患者进行研究"}, {"probability": {"variance": 8.8e-05, "average": 0.996074, "min": 0.939366}, "location": {"width": 878, "top": 1391, "height": 64, "left": 239}, "words": "年龄:在20~80岁的受试者中进行年龄影响的研究。加巴喷丁的表观口服清除率(CL/F)随着年龄增加而下"}, {"probability": {"variance": 4.9e-05, "average": 0.993599, "min": 0.981733}, "location": {"width": 93, "top": 1430, "height": 23, "left": 848}, "words": "肾脏清除率"}, {"probability": {"variance": 0, "average": 0.999229, "min": 0.997942}, "location": {"width": 110, "top": 1423, "height": 23, "left": 1007}, "words": "和根据体表调"}, {"probability": {"variance": 1.5e-05, "average": 0.997012, "min": 0.983939}, "location": {"width": 291, "top": 1448, "height": 38, "left": 194}, "words": "降了,从在30岁以下的人中大约22"}, {"probability": {"variance": 9e-06, "average": 0.998233, "min": 0.987672}, "location": {"width": 247, "top": 1435, "height": 35, "left": 529}, "words": "in到70岁以上的人中大约125"}, {"probability": {"variance": 0.003181, "average": 0.987016, "min": 0.620666}, "location": {"width": 923, "top": 1448, "height": 66, "left": 196}, "words": "整过的肾脏清除率也随着年龄的增加而降低;然而,加巴喷丁的肾脏清除率随着年龄下降在很大程度上能解释为肾"}, {"probability": {"variance": 0.00176, "average": 0.991309, "min": 0.754962}, "location": {"width": 611, "top": 1491, "height": 52, "left": 195}, "words": "脏功能的下降。有与年龄相关的肾脏功能疾病患者中要求减少加巴喷丁剂量"}, {"probability": {"variance": 0.000114, "average": 0.996671, "min": 0.92965}, "location": {"width": 861, "top": 1508, "height": 61, "left": 244}, "words": "儿科:加巴喷丁的药物代谢动力学在48名年龄在1个月到12岁的儿科的受试者中进行,剂量约为10mg/kg"}], "language": 3}